# Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

> **NCT02476123** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)

## Key facts

- **NCT ID:** NCT02476123
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-02-07
- **Final completion:** 2018-12-21
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2019-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476123, "Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02476123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*